Pulse Brain · Growing Health Evidence Index
Peer-reviewed

Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma

Charlotte S. Voskuilen, Htoo Zarni Oo, Vera Genitsch, Laura A. Smit, A. Vidal, Manuel Meneses, Andrea Necchi, Maurizio Colecchia, Évanguelos Xylinas, Jacqueline Fontugne, Mathilde Sibony, Morgan Rouprêt, Louis Lenfant, Jean‐François Côté, Lorenz Buser, Karim Saba, Marc A. Furrer, Michiel S. van der Heijden, Mads Daugaard, Peter C. Black, Bas W.G. van Rhijn, Kees Hendricksen, Cédric Poyet, Roland Seiler

The American Journal of Surgical Pathology · 2019

Read source ↗ All evidence

Summary

Response classification after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma is based on the TNM stage at radical cystectomy. We recently showed that histopathologic tumor regression grades (TRGs) add prognostic information to TNM. Our aim was to validate the prognostic significance of TRG in muscle-invasive bladder cancer in a multicenter setting. We enrolled 389 patients who underwent cisplatin-based chemotherapy before radical cystectomy in 8 centers between 2010 and 2016. Median follow-up was 2.2 years. TRG was determined in radical cystectomy specimens by local pathologists. Central pathology review was conducted in 20% of cases, which were randomly selected. The major response was defined as ≤pT1N0. The remaining patients were grouped into partial responders (≥ypT2N0-3

Source type
Peer-reviewed study
DOI
10.1097/pas.0000000000001371
Catalogue ID
BFmoef2rp2-snm17b
Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.